Aviceda Therapeutics

Aviceda is an innovative clinical-stage biotech company focused on the next generation of glyco-immune therapeutics for patients with immune system dysfunction.

[Aviceda Therapeutics @avicedarx]

Catch this profile of Aviceda Therapeutics Co-Founder Michael J. Tolentino, MD, in @USAToday. #glycoimmunology #biotech #innovation #ophthalmology #retina #GA #AMD #macula

https://t.co/wKB9fNXMkw

[Aviceda Therapeutics @avicedarx]

Sun, fun, and teamwork! 📷 The Aviceda Team had an incredible day bonding over a scavenger hunt, kayaking along the Charles River, and enjoying dinner at the Glass House in Cambridge. These experiences strengthen our team spirit and creativity and recharge our batteries.

[Aviceda Therapeutics @avicedarx]

Rishi Singh, MD, reviews findings from the Phase 2a SIGLEC study assessing the safety and efficacy of AVD-104 for geographic atrophy secondary to AMD at this year’s #ASRS2024 meeting in Stockholm #glycoimmunology #biotech #innovation #ophthalmology #retina
https://t.co/YZrdjSwFwP

[Aviceda Therapeutics @avicedarx]

At ASRS on Thursday, July 18, at 1:24 pm, Rishi Singh, MD, will share safety and efficacy results from the Phase 2a SIGLEC trial assessing AVD-104 for geographic atrophy secondary to AMD. #glycoimmunology #biotech #innovation #ophthalmology #retina #GA #AMD #macula

[Aviceda Therapeutics @avicedarx]

At ASRS on Thursday, July 18, at 1:28 pm, David Boyer, MD, will explore anatomic changes in GA patients who received a single injection of AVD-104 in the phase 2a SIGLEC study. #glycoimmunology #biotech #innovation #ophthalmology #retina #GA #AMD #macula

[Aviceda Therapeutics @avicedarx]

Aviceda wishes everyone a Happy Fourth of July! Enjoy the day with your family and friends—and be sure to rest up for a busy summer ahead.

#retina
#glycoimmunology
#biotech
#innovation
#ophthalmology
#GA
#AMD
#macula

[Aviceda Therapeutics @avicedarx]

Join us on Saturday June 8, at 10:27am as David Callanan, MD, sits on a panel moderated by Jeffrey Heier, MD. They will explore the state of play in geographic atrophy and explore what the next generation of therapies could (and should) look like #glycoimmunology #ophthalmology

[Aviceda Therapeutics @avicedarx]

Join us on Saturday, June 8, at 10:07am for Clinical Trials at the Summit as Tarek Hassan, MD, takes the stage to explore how a new approach to treating geographic atrophy could lead to a paradigm shift in disease treatment #glycoimmunology #ophthalmology #retina #GA #AMD #macula

[Aviceda Therapeutics @avicedarx]

At Clinical Trials at the Summit on Saturday, June 8, at 10:11am, Arshad Khanani, MD, MA, will explore the findings of the SIGLEC Phase 2a study. #glycoimmunology #biotech #innovation #ophthalmology #retina #GA #AMD #macula

[Aviceda Therapeutics @avicedarx]

Don’t miss the late-breaker session on Sunday, May 12, at Retina World Congress. Robert Avery, will present the latest data from Part 1 of the Phase 2/3 SIGLEC study assessing AVD-104 for the treatment of geographic atrophy secondary to AMD. #geographicatrophoy #retina

[Aviceda Therapeutics @avicedarx]

David Callanan, MD Chief Medical Officer at Aviceda Therapeutics, will be part of the RWC Unplugged Panel on Thurs, 5/9, discussing geographic atrophy at this year’s Retina World Congress. Join him to hear his insights about the future of #geographicatrophy treatments in #retina

[Aviceda Therapeutics @avicedarx]

Congratulations to Kinkini Roy, PhD, for leading an excellent presentation titled “Surface-modified LNP: Stability & Characterization” at this year’s LNP Formulation and Process Development Summit in Boston! Once again, the Aviceda team helps lead the conversation on innovation.

[Aviceda Therapeutics @avicedarx]

Work from the Aviceda Therapeutics team has been published once again in the journal Pharmaceuticals. Read it here: https://t.co/046v2gbN1M #glycoimmunology #biotech #innovation #ophthalmology #retina

[Aviceda Therapeutics @avicedarx]

The team at Aviceda Therapeutics is proud to announce the publication of a new manuscript in the journal Pharmaceuticals. You can read the journal entry here: https://t.co/0VI1G1Lrl4 #glycoimmunology #biotech #innovation #ophthalmology #retina

[Aviceda Therapeutics @avicedarx]

Aviceda Therapeutics Announces Formation of Renowned European Clinical Advisory Board https://t.co/Tw24ZM1LYd #glycoimmunology #biotech #innovation #ophthalmology #retina #GA #AMD #macula

[Aviceda Therapeutics @avicedarx]

Don’t miss Chief Development Officer Tarek Hassan, MD, as he accepts his Lifetime Achievement Award from the Vit-Buckle Society at #VBS2024! Dr. Hassan will take the stage at 11:10am ET to deliver his lecture “Nobody Normal Ever Accomplished Anything.”

[Aviceda Therapeutics @avicedarx]

On April 10, the Aviceda Executive Team will participate in the 23rd Annual Needham Virtual Healthcare Conference. Our Chief Medical Officer David Callanan, MD, will present an update on AVD-104 and the SIGLEC GA trial, covering #glycoimmunology in #ophthalmology and beyond.

[Aviceda Therapeutics @avicedarx]

In the most recent issue of CXO Outlook, Aviceda’s CEO and Co-founder Mohamed Genead, MD, was profiled as the Most Inspiring Business Leader for 2024. Read more: https://t.co/mj4aIQeRv8 #glycoimmunology #biotech #innovation #ophthalmology #retina #GA #AMD #macula

[Aviceda Therapeutics @avicedarx]

This week, Aviceda Therapeutics participated in a virtual fireside chat with Truist about the dynamics in the marketplace for geographic atrophy. Watch the interview here:  https://t.co/08umhGCnH6 #glycoimmunology #biotech #innovation #ophthalmology #retina #GA #AMD #macula

[Aviceda Therapeutics @avicedarx]

Join Tarek Hassan, MD, at the #BRAVS2024 meeting in Campinas, Brazil, as he discusses how glyco-immune macrophage modulation could be key to unlocking the next era of geographic atrophy treatment. #glycoimmunology #biotech #innovation #ophthalmology #retina #GA #AMD #macula